Review article: Management of mild and severe gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 17, Issue 2, 2003, Pages 52-56

  Tytgat, G N J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CONFERENCE PAPER; DISEASE SEVERITY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAINTENANCE DRUG DOSE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; REFLUX ESOPHAGITIS; RELAPSE; SLEEP DISORDER; TREATMENT PLANNING;

CLINICAL TRIALS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMPS;

EID: 0037560062     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Fass R, Ofman JJ. Gastroesophageal Reflux Disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-9.
2. Quigley EMM. Non-erosive reflux disease, part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13: S13-S18.
3. Hunt RH. Habit, prejudice, power and politics. Issues in the conversion of H2-receptor antagonists to over-the-counter use. Can Med Assoc J 1996; 154: 49-53.
4. Paul K, Redman CM, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther 2001; 15: 1571-7.
5. Robinson M, Rodriguez-Stanley S, Ciociola AA, et al. Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced hearburn. Aliment Pharmacol Ther 2001; 15: 1365-74.
6. Howden CW, Henning JM, Huang B, et al. Management of heartburn in a large, randomized, community-based study: Comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 1704-10.
7. McGuigan JE. Treatment of gastroesophageal reflux disease: to step or not to step. Am J Gastroent 2001; 96: 1679-82.
8. Beck IT. In support of 'step-up therapy' for gastroesophageal reflux disease. AJG 2002; 97: 503-4.
9. Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11: 541-6.
10. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160: 1803-9.
11. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-73.
12. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary car: An international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
13. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease. A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73.
14. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomised placebo-controlled trial. Am J Gastroent 2002; 97: 1332-9.
15. Katz PO, Catell DO, Marino V, et al. Comparison of the new PPI esomeprazole, the S-isomiser of omeprazole, vs. placebo for the treatment of symptomatic GERD. Am J Gastroenterol 2000; 95: 2424-5. (Abstract)
16. Johnston BT, McFarland RJ, Collins JS, et al. Symptoms index as a marker of gastro-oesophageal reflux disease. Br J Surg 1992; 79: 1054-5.
17. Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001; 13: S19-S22.
18. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
19. Talley NJ, Lauritsen K, Tunturi-Hihnalas H, et al. Esomeprazole 20 mg maintains symptom control in edoscopy-negative gastro-oesophageal reflux disease, a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54.
20. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomised controlled trial. Am J Gastroenterol 2001; 96: 654-64.
21. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial. Aliment Pharmacol Ther 2000; 12: 1249-58.
22. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-82.
23. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomised controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15: 227-31.
24. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-36.
25. Dekkers CP, Beker JA, Thjodleifsson B, et al. Double-blind, placebo-controlled comparisons of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57.
26. Delchier J-C, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand J Gastroenterol 2000; 35: 1245-50.
27. Howden CW, Ballard IIED, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22: 99-109.
28. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
29. Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drug: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473-82.
30. Tytgat GNJ. Possibilities and shortcomings of maintenance therapy in gastoesophageal reflux disease. Dig Surg 1999; 16: 1-6.
31. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-36.
32. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62: 1503-38.
33. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomised, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
34. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomised, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34.
35. Lauritsen K, Deviere J, Bigard H-A, et al. Esomeprazole 20 mg and Lansoprazole 15 mg in maintaining healed reflux oesophagitis. Metropole Study Results. Aliment Pharmacol Ther 2003; 17: 333-41.
36. Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol 2002; 97: 1357-64.
37. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M. On-demand treatment in patients with oesophagitis and reflux symptoms: Comparison of lansoprazole and omeprazole. Scan J Gastroenterol 2002; 37: 642-7.
38. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterlogy 2001; 121: 1095-100.
39. Xue S, Katz PO, Banerjee P, Tutuian R, Castefl DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
40. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.